SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:liu-134620"
 

Sökning: id:"swepub:oai:DiVA.org:liu-134620" > Work productivity l...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004979naa a2200553 4500
001oai:DiVA.org:liu-134620
003SwePub
008170221s2016 | |||||||||||000 ||eng|
009oai:DiVA.org:uu-280015
009oai:prod.swepub.kib.ki.se:135021767
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1346202 URI
0247 a https://doi.org/10.1007/s10198-015-0749-y2 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2800152 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1350217672 URI
040 a (SwePub)liud (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Banefelt, J.u Quantify Research, Sweden4 aut
2451 0a Work productivity loss and indirect costs associated with new cardiovascular events in high-risk patients with hyperlipidemia: estimates from population-based register data in Sweden
264 c 2015-11-25
264 1b SPRINGER,c 2016
338 a electronic2 rdacarrier
500 a Funding Agencies|Amgen, Inc.
520 a Objectives To estimate productivity loss and associated indirect costs in high-risk patients treated for hyperlipidemia who experience cardiovascular (CV) events. Methods Retrospective population-based cohort study conducted using Swedish medical records linked to national registers. Patients were included based on prescriptions of lipid-lowering therapy between 1 January 2006 and 31 December 2011 and followed until 31 December 2012 for identification of CV events and estimation of work productivity loss (sick leave and disability pension) and indirect costs. Patients were stratified into two cohorts based on CV risk level: history of major cardiovascular disease (CVD) and coronary heart disease (CHD) risk equivalent. Propensity score matching was applied to compare patients with new events (cases) to patients without new events (controls). The incremental effect of CV events was estimated using a difference-in-differences design, comparing productivity loss among cases and controls during the year before and the year after the cases event. Results The incremental effect on indirect costs was largest in the CHD risk equivalent cohort (n = 2946) at (sic)3119 (P value amp;lt;0.01). The corresponding figure in the major CVD history cohort (n = 4508) was (sic)2210 (P value amp;lt;0.01). There was substantial variation in productivity loss depending on the type of event. Transient ischemic attack and revascularization had no significant effect on indirect costs. Myocardial infarction ((sic)), unstable angina ((sic)) and, most notably, ischemic stroke ((sic)) yielded substantial incremental cost estimates (P values amp;lt;0.01). Conclusions Indirect costs related to work productivity losses of CV events are substantial in Swedish high-risk patients treated for hyperlipidemia and vary considerably by type of event.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng
650 7a SAMHÄLLSVETENSKAPx Ekonomi och näringsliv0 (SwePub)5022 hsv//swe
650 7a SOCIAL SCIENCESx Economics and Business0 (SwePub)5022 hsv//eng
653 a Cardiovascular disease; Hyperlipidemia; Indirect costs; Productivity
7001 a Hallberg, S.u Quantify Research, Sweden4 aut
7001 a Fox, K. M.u Strateg Healthcare Solut LLC, MD USA4 aut
7001 a Mesterton, J.u Karolinska Institutet4 aut
7001 a Paoli, C. J.u Amgen Inc, CA 91320 USA4 aut
7001 a Johansson, Gunnaru Uppsala universitet,Allmänmedicin och preventivmedicin,Uppsala University, Sweden4 aut0 (Swepub:uu)gunnarjs
7001 a Levin, Lars-Åkeu Linköpings universitet,Avdelningen för hälso- och sjukvårdsanalys,Medicinska fakulteten4 aut0 (Swepub:liu)larle77
7001 a Sobocki, P.u Karolinska Institute, Sweden; IMS Heatlh, Sweden4 aut
7001 a Gandra, S. R.u Amgen Inc, CA 91320 USA4 aut
7102 a Quantify Research, Swedenb Strateg Healthcare Solut LLC, MD USA4 org
7730 t European Journal of Health Economicsd : SPRINGERg 17:9, s. 1117-1124q 17:9<1117-1124x 1618-7598x 1618-7601
8564 u https://liu.diva-portal.org/smash/get/diva2:1075937/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://link.springer.com/content/pdf/10.1007/s10198-015-0749-y.pdf
8564 u https://doi.org/10.1007/s10198-015-0749-yy Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:909492/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-134620
8564 8u https://doi.org/10.1007/s10198-015-0749-y
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-280015
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:135021767

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy